Please assess the completion status of the following clinical trial:

Trial Title: Multi-cap for Increase Adherence After Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old~* Myocardial infarction within seven (7) days prior: anginal symptoms with ST-segment changes (elevation or depression) or inversion of T waves or left bundle branch block and acute elevation of cardiac enzymes.~* Signature of written informed consent~Exclusion Criteria:~* Severe ventricular dysfunction, (ejection fraction of the left ventricle less than 40%)~* Contraindication for beta-blockers, angiotensin-converting enzyme, aspirin and / or statins.~* History of allergies or adverse reactions to some of the study drug reactions. Chronic treatment with NSAIDs. Planned coronary-revascularization within six months after discharge.~* Renal failure with estimated creatinine clearance according to the Cockroft-Gault formula less than 30 ml / min.~* Liver or elevated transaminases before randomization more than three times the upper normal limit.~* Higher fasting triglycerides 500 mg / dl.~* Indication according to medical criteria other than a beta-blocker atenolol.~* Indication of oral anticoagulation.~* Failure to follow due to difficulties of geographical access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Combined capsule (Type: EXPERIMENTAL): Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
- Conventional treatment (Type: OTHER): Usual therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).